Trial Profile
A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) - (KEYNOTE 173)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- Acronyms KEYNOTE 173; MK-3475-173/KEYNOTE 173
- Sponsors Merck Sharp & Dohme
- 25 Nov 2019 Status changed from active, no longer recruiting to completed.
- 29 Sep 2019 According to Merck's media release KEYTRUDA plus chemotherapy was granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the neoadjuvant treatment of patients with high-risk, early-stage TNBC
- 09 May 2018 Planned End Date changed from 16 Jun 2018 to 4 Nov 2019.